Idioma:

Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs

Alabi, Shanique B. ; Crews, Craig M.

The Journal of biological chemistry, 2021-01, Vol.296, p.100647-100647, Article 100647 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por

Título:
Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs
Autor: Alabi, Shanique B. ; Crews, Craig M.
Assuntos: AUTACs ; chemical biology ; drug action ; JBC Reviews ; lysosome ; LYTACs ; molecular glues ; PROTACs ; protein degradation ; ubiquitination
É parte de: The Journal of biological chemistry, 2021-01, Vol.296, p.100647-100647, Article 100647
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Descrição: Of late, targeted protein degradation (TPD) has surfaced as a novel and innovative chemical tool and therapeutic modality. By co-opting protein degradation pathways, TPD facilitates complete removal of the protein molecules from within or outside the cell. While the pioneering Proteolysis-Targeting Chimera (PROTAC) technology and molecular glues hijack the ubiquitin-proteasome system, newer modalities co-opt autophagy or the endo-lysosomal pathway. Using this mechanism, TPD is posited to largely expand the druggable space far beyond small-molecule inhibitors. In this review, we discuss the major advances in TPD, highlight our current understanding, and explore outstanding questions in the field.
Editor: United States: Elsevier Inc
Idioma: Inglês

Links

Voltar para lista de resultados